Mazdutide Investigated for Treating Polycystic Ovary Syndrome in Obese Women

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder affecting women, characterized by hormonal imbalances, anovulation (lack of ovulation), and hyperandrogenism (excess male hormones). It frequently leads to infertility, metabolic dysfunction, and is strongly associated with obesity. While current treatments often manage symptoms, there remains a significant need for therapies that address the underlying hormonal and metabolic dysregulation, especially in obese patients. This study aims to evaluate if Mazdutide can effectively reduce the Free Androgen Index (FAI) in obese women with PCOS.

This ongoing Phase 1/2 clinical trial is designed to assess the efficacy of Mazdutide in obese women with PCOS, with results anticipated upon completion. The primary endpoint is the change in the Free Androgen Index (FAI), a key marker of hyperandrogenism, measured at the 24-week timepoint. Researchers hypothesize that Mazdutide treatment will lead to a significant reduction in FAI compared to baseline values in the study participants. While specific results are not yet available as the study is actively recruiting, the trial aims to establish whether Mazdutide can achieve a clinically meaningful decrease in FAI. The study's success will be determined by the magnitude of FAI reduction observed after 24 weeks of treatment. > The study's primary objective is to determine if Mazdutide can significantly lower the Free Androgen Index (FAI) in obese female adults with PCOS after 24 weeks of treatment.